Chemotherapy's hidden impact on body reflexes revealed
NCT ID NCT07069790
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how chemotherapy changes certain nerve reflexes that control blood pressure and exercise responses in breast cancer patients. Researchers will compare 24 women who recently finished chemotherapy with healthy volunteers. The goal is to understand these changes so that personalized exercise programs can be created to help patients recover better.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could help design personalized exercise programs to improve cardiovascular function and reduce side effects in breast cancer survivors.
- What could go wrong
- This is a small, early-stage observational study with only 24 participants, so results may not apply to all patients. It measures physiological responses, not a treatment, so direct patient benefit is not guaranteed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 24 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2025
- Expected to finish
-
Oct 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Patient group : * Stage I to III breast cancer * Having completed (neo)adjuvant chemotherapy treatment less than three weeks ago Control group : \- healthy women (no history of cancer) of similar age, weight, and physical activity level Exclusion Criteria: * History of cancer * Any known chronic pathology * Protected minor or adult * Psychiatric, musculoskeletal or neurological problems * Implantation of a pacemaker * Pregnant woman * Presenting at least one contraindication to the use of transient blood flow occlusion
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast adenocarcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Institut de cancérologie Strasbourg Europe
RECRUITINGStrasbourg, 67100, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a 3-Week radiation course beat 5 weeks for breast cancer patients with reconstruction?
- Triple threat: new combo shows promise against tough breast cancer
- Could adding carboplatin to chemo keep triple-negative breast cancer away?
- Can MRI scans be safe with breast expanders? new study aims to find out
- Immune booster before chemo shows promise for tough breast cancer
- CBD oil tested for breast cancer drug side effect